Em. Manolescu *, Smaranda Petrescu *
* Prof. Dr. Emanoil Manolescu, Dr. Smaranda Petrescu – Catedra de Farmacologie UMF “Carol Davila” București
Abstract
Fluvastatin (Lescol), a member of the group of drugs known as HMG-CoA reductase inhibitors, is used in the treatment of patients with hypercholesterolaemia. In patients with primary hypercholesterolaemia, fluvastatin achieved marked reductions from baseline in serum levels of LDL-cholesterol and total cholesterol, along with modest declines in serum triglyceride levels and small increases in HDL-cholesterol levels. Fluvastatin is effective and well tolerated in patients with hypercholesterolaemia and appears to have an economic advantage over other HMG-CoA reductase inhibitors, primarily as a result of its relatively low acquisition costs.